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Abstract
Background: Treatment strategies for Retinoblastoma (RB), the most common primary intraocular tumor in
children, have evolved over the past few decades and chemoreduction is currently the most popular treatment
strategy. Despite success, systemic chemotherapeutic treatment has relevant toxicity, especially in the pediatric
population. Antiangiogenic therapy has thus been proposed as a valuable alternative for pediatric malignancies, in
particolar RB. Indeed, it has been shown that vessel density correlates with both local invasive growth and
presence of metastases in RB, suggesting that angiogenesis could play a pivotal role for both local and systemic
invasive growth in RB. We present here two cases of sporadic, bilateral RB that did not benefit from the
conservative treatment and we provide evidence that the VEGF-A pathway is significantly up-regulated in both RB
cases along with an over expression of hERG1 K+ channels.
Case presentation: Two patients showed a sporadic, bilateral RB, classified at Stage II of the Reese-Elsworth
Classification. Neither of them got benefits from conservative treatment, and the two eyes were enucleated. In
samples from both RB cases we studied the VEGF-A pathway: VEGF-A showed high levels in the vitreous, the vegf-
a, flt-1, kdr, and hif1-a transcripts were over-expressed. Moreover, both the transcripts and proteins of the hERG1 K+
channels turned out to be up-regulated in the two RB cases compared to the non cancerous retinal tissue.
Conclusions: We provide evidence that the VEGF-A pathway is up-regulated in two particular aggressive cases of
bilateral RB, which did not experience any benefit from conservative treatment, showing the overexpression of the
vegf-a, flt-1, kdr and hif1-a transcripts and the high secretion of VEGF-A. Moreover we also show for the first time
that the herg1 gene transcripts and protein are over expressed in RB, as occurs in several aggressive tumors. These
results further stress the relevance of the VEGF-A pathway in RB and the correlation with hERG1, making aggressive
and recurrent RB cases good candidates for antiangiogenesis therapies based on the targeting of VEGF-A.
Background
Retinoblastoma (RB) is the most common primary
intraocular tumor in children, with an incidence of 1 in
15,000 live births. The retinoblastoma protein (Rb) regu-
lates cell cycle progression and suppresses tumorigenesis
through the control of E2F transcription factor function,
which in turn represents the link between the Rb path-
way and the induction of p53-dependent apoptosis [1].
RB can affect one or both eyes, and may show either
endophytic or exophytic growth, sometimes with signs
of invasiveness. When tumor cells invade the choroid or
the optic nerve thus reaching the sclera or the lamina
cribrosa, extraocular growth can occur. Through this
mechanism, tumor cells can spread to the brain, the sur-
rounding head bones, or soft tissues. In rare cases, RB
disseminates in the whole body giving rise to distant
metastases in the bone marrow, liver or skeletal system.
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In any case, invasion of either the choroid or the optic
nerve are risk factors for developing metastases [2-6].
Treatment strategies for RB have gradually evolved
over the past few decades. There has been a trend
away from enucleation and external beam radiation
therapy toward focal ‘conservative’ treatments, invol-
ving primary chemoreduction in conjunction with
thermotherapy and cryotherapy [7-11]. This is related
to earlier detection of the disease, recognition of more
effective chemotherapeutic agents, more focused local
treatment modalities, and, most importantly, knowl-
edge of the long-term risks of external beam radiother-
apy. Furthermore, recent research in the treatment of
RB has concentrated on methods of combining che-
motherapy with other local treatment modalities. This
approach combines the principle of chemotherapeutic
debulking in paediatric oncology with conservative
focal therapies in ophthalmology. Chemoreduction is
currently the most popular treatment strategy for
intraocular RB worldwide. Despite the dramatic clinical
responses obtained with multiagent systemic che-
motherapy regimens, enthusiasm for this treatment
approach has been tempered by the potential toxicities
of these drugs in the pediatric population [12].
Antiangiogenic therapy has been proposed as a valu-
able tool for solid tumors, including pediatric malignan-
cies. In particular, RB tumors are excellent targets for
antiangiogenic therapy. Numerous studies have demon-
strated that the vascular density of a tumor correlates
with the onset of metastases and hence to poor out-
come. It has been shown that vessel density correlates
with both local invasive growth and presence of metas-
tases in RB [13]. These data suggest that angiogenesis
plays a pivotal role for both local and systemic invasive
growth in RB [12-17]. One of the most potent angio-
genic factor is the vascular endothelial growth factor-A
(VEGF-A). Hence VEGF-A represents one of the most
powerful targets in antiangiogenesis therapy. Indeed in a
retrospective study on several RB cases [14] was
reported a positive correlation between VEGF-A staining
intensity and different clinico-pathological markers of
malignancy (mitotic and apoptotic indexes).
Herein we present two cases of sporadic, bilateral RB:
both of them were endophitic and characterized by an
elevated grade of differentiation. Nevertheless both cases
did not benefit from the conservative treatment. We
provide evidence that the VEGF-A pathway is signifi-
cantly up-regulated in both RB cases along with an over
expression of hERG1 K+ channels.
Methods
VEGF-A secretion
The level of VEGF-A was determined in the vitreous
fluid collected during the enucleation, using the DuoSet
ELISA Development System (R&D Systems, Wiesbaden,
Germany).
RNA extraction and RT-PCR
Normal and neoplastic tissue from the same patient
were homogenized in a guanidinium thiocyanate solu-
tion, and total RNA was extracted according to [18].
cDNA was then synthesized from 2 μg of RNA using
200 U reverse transcriptase SuperScript II (Invitrogen,
Groningen, The Netherlands), plus 200 μM each of
dNTP and 2.5 μM random hexamers, in a 20 μl final
reaction volume, for 50 min at 42°C and 15 min at 70°C.
Real-Time Quantitative PCR (RQ-PCR)
Vegf-a, flt-1, kdr, gapdh, hif-a herg1a and herg1b mRNA
were quantified in both normal and neoplastic tissue by
RQ-PCR, with the ABI PRISM 7700 Sequence Detection
System and the SYBR Green Master Mix Kit (Applied
Biosystems, Foster City, CA) as reported in [19]. The
primer sequences were as follows:
Vegf-a sense CGAAACCATGAACTTTCTGC,
antisenseCCTCAGTGGGCACACACTCC;
hif-a sense GTCGCTTCGGCCAGTGTG antisense
GGAAAGGCAAGTCCAGAGGTG; flt1, kdr, gapdh,
herg1a, and herg1b primer sequences were as reported
in [19]. The level of transcripts in the normal retina of
each case was taken as 1.
Immunohistochemistry (IHC)
Tumor specimens were processed for histological analy-
sis and stained with Hematoxylin and Eosin. IHC was
performed as previously reported in [20] on 5-μm sec-
tions attached to positive-charged microscope slides.
After dewaxing and re-hydrating, the specimens were
treated with a 1% H2O2 solution and antigen retrieval
was carried out using: a) Proteinase K solution (5 μg/ml
in PBS)(Roche, Milan, Italy) for VEGF-A and hERG1
staining; b) microwave treatment in 10 mM Na citrate
(pH 6.0) at 700 W for 10 minutes, twice for CD34 and
Ki-67 staining. Permeabilization was performed with
0.1% Triton X100 in UltraVBlock (LabVision, Fremont,
CA). The antibodies were: anti VEGF polyclonal anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA;
1:200), anti CD34 monoclonal antibody (Cederlane,
Ontario, Canada; 1:100), anti Ki-67 monoclonal antibody
(DCS Innovative Diagnostik-Systeme, Hamburg, Ger-
many; 1:100), anti hERG1 monoclonal antibody, clone
A12 (Enzo Life Sciences, Lausen, Switzerland; 1:100).
Incubation was carried out at 4°C O/N. Detection was
carried out with PicTure Plus Kit (Zymed, Milan, Italy)
and DAB chromogen solution (Zymed, Milan, Italy),
according to the manufacturer’s instructions.
For immunostaining analysis, tumors were scored by
assessment of the proportion and intensity of stained
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tumor cells and then scored by a semiquantitative
method as reported in [14]. The positive staining is
shown as a brown pigment, localised in the cytoplasm
of cells. Positively stained cells were counted in 5 ran-
domly selected fields under a magnification of 400×.
To assess cell apoptosis we analyzed DNA breaks in
apoptotic nuclei using the FragEL DNA fragmentation
Detection Kit (Calbiochem, San Diego, CA, USA).
The apoptotic index (AI,%) and the proliferation index
(PI, %) were calculated by counting 100 cells (× 400)
using FrageEL method and Ki-67 staining, respectively.
Microvessel density was calculated by counting CD34
positive vessels on microscopic field (200×
magnification).
Cases presentation
In this study we describe two cases of RB that came to
our observation in the period 2000-2010. At difference
from the 15 cases which were examined and cured in
the Department of Pediatric Ophthalmology Meyer Hos-
pital of Florence in the same period, the two cases here
presented did not benefit from the conservative treat-
ment. Both cases were sporadic, bilateral, endophitic RB,
whose histological evaluation revealed an elevated grade
of differentiation so that they were classified as Stage II
of the Reese-Elsworth Classification.
Case 1
An 1 year old male with no family history of RB had
right leukocoria at presentation. The first examination
revealed a solid mass which occupied the vitreous cavity,
and caused a great inferior retinal detachment. There
was no evidence of vitreous seeding. Intraocular pres-
sure (IOP) elevation was detected in the right eye. The
right eye was enucleated and substituted by an hidros-
siapatite implant. Histopathologic examination revealed
an elevated grade of differentiation of the tumor without
infiltration of the optic disc. In the left eye, we observed
a little tumor near the inferior vascular arch, at 1 optic
disc distance from the fovea, and another little tumor
near the superior vascular arch.
Genetic analysis (FISH fluorescence In Situ Hybridiza-
tion Retinoblastoma DNA Probe 13q14) demonstrated
the absence of RB1 gene delection.
The left eye was treated with chemotherapy associated
with focal laser treatment. The AIEOP/RTB-92 Treat-
ment Protocol (4 cycles regimen consisting of Carbopla-
tin (165 mg/kg/die) and VP16 (50 mg/kg/die for 2
days)) was applied. An examination at the end of che-
motherapy with B-scan ecography confirmed a partial
reduction of both tumor size (from 5,5 mm to less then
4 mm) and thickness (from 2 mm to 1 mm). At the end
of chemotherapy, a laser treatment around the tumor
mass in the left eye was applied using 450-600 mW,
with a spot of 600μ. Subsequently, fundus examination
revealed the presence of a tumor in a phase of “cottage
cheese” and a ipopigmented atrophic area near the trea-
ted areas. Patient was then evaluated every 3 months for
the the first year, and every six months starting from
the second year. No signs of disease were detected. At
the 5 years follow-up, we observed a very aggressive
recurrence in a new site at the B-scan ecography (Figure
1A). Fundus examination of the left eye revealed the
presence of a new great tumor mass (9,77 mm height
and 12 mm at the base) in the superior quadrant, with
partial detachment of the surrounding retina (Figure
1A’). This recurrence was treated with chemotherapy (6
cycles of IVad: VCR 1,50 mg/push in 15 ml Sol. Gluc.
5% in 10’ Adriblastin 15 mg in 100 ml SF; MESNA 800
mg in 20 ml SF/push; Ifosfamide 2000 mg in 1 vial/20
Figure 1 B scan echography and fundus photograph of the
recurrence of case 1 at 5 years follow-up. (A) B scan echography
showing a great tumoral mass with calcification in the superior
sector at 5 years follow-up. (A’) Fundus photograph showing large
tumor mass at 5 years follow-up.
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ml; with preidratation and idratation after the infusion
of the chemotherapy) and, subsequently, with cryother-
apy. After cryotherapy, we observed a reduction in the
tumor size, paralleled by an increased retinal detach-
ment and presence of fibrin in the anterior chamber,
that impaired any further examination of the fundus. 30
days after, when the fibrin clot in the anterior chamber
was reduced, we observed numerous little new tumors,
widespread in the retinal tissue. Given the intraocular
dissemination of the tumor, the left eye was enucleated.
Case 2
An 8 months old female with no family history of RB
had bilateral leukocoria at presentation. The first exami-
nation revealed three masses of medium dimension at
700 μ distance from the fovea, with retinal detachment
in the right eye and a mass (whose dimensions were
1.01 × 1.03 × 1.22 cm) in the left eye. The mass occu-
pied 50% of the vitreous cavity and was associated with
retinal detachment and vitreal seeding (Figure 2).
Nuclear Magnetic Resonance (NMR) showed a large cal-
cified mass with no evidence of invasion of the optic
nerve. No metastases were detectable.
The left eye was enucleated according to the AIEOP/
RB 05 Treatment Protocol. The histological examination
revealed an elevated grade of differentiation of the
tumor without infiltration of the optic disc. RB1 gene
analysis on peripheral blood lymphocytes demonstrated
deletion of exon 24. At the end of the third cycle of
chemotherapy the tumors in the right eye were partially
reduced (50% of tumor size) and cryotherapy and laser
therapy were utilized. Patient was evaluated every 3
months for the the first year, and every six months
starting from the second year. Two years later we
observed a new aggressive recurrence in the right eye
but, unlike Case 1, we decided to treat this patient
according to the more recent aquisitions in literature
[21]. Therefore, the patient was assigned to receive tan-
dem HDCT/ASCR (high-dose chemotherapy/autologous
stem cell rescue). The right eye at the moment (4
months from the end of therapy) shows a modest reduc-
tion of dimension of recurrence, between still accom-
pained by a subtotal retinal detachment.
In both RB samples we studied the VEGF-A pathway,
determining the expression level of the vegf-a, VEGF-A
receptors (flt-1 and kdr) and hif1-a transcripts. The RQ-
PCR technique was applied and results were compared
with the expression level of the corresponding normal
retina. The vegf-a transcript was over-expressed in both
cases (3.8 fold increase in case 1; 51.9 fold in case 2).
Both flt-1 and kdr were expressed in both RB samples at
levels higher than normal retina (flt1: 2.8 folds in case 1,
8.1 folds in case 2, median value 5.5; kdr: 5.5 folds in
case 1, 2.1 folds in case 2, median value 3.8). Finally, the
hif1-a transcript was over-expressed in both samples (11
fold in case 1), with higher levels in case 2 (76 fold).
Both isoforms of the herg1 gene (herg1a and herg1b)
were over-expressed compared to the corresponding
normal retina. The full length isoform herg1a was
expressed at higher levels compared to the herg1b tran-
script (herg1a: 17.1 folds in case 1, 150 folds in case 2,
median value 83.6; herg1b: 4.3 folds in case 1, 15 folds
in case 2, median value 9.7). Finally, both isoforms were
expressed at higher levels in case 2 (Figure 3A).
We then evaluated the levels of VEGF-A in the vitr-
eous fluid obtained during the enucleation of both
cases. The levels of VEGF-A were 854 ± 83 pg/ml in
case 1 and 1120 ± 98 pg/ml in case 2, respectively
Figure 2 Nuclear Magnetic Resonance (NMR) and fundus
photograph of case 2 at presentation. (A) NMR evidenced a
large calcified mass with no invasion of the optic nerve in the left
eye and three tumors of medium and little dimension in the right
eye (two of them are very close to each other, so that they seem as
a unique mass). (A’) Fundus photograph obtained before
chemotherapy showing large tumor mass that occupied more than
50% of the vitreous cavity in the left eye.
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Figure 3 Analysis of the VEGF-A pathway in the two cases. (A) mRNA expression levels of vegf-a, flt-1, kdr, hif-a, herg1a and herg1b in the RB
tumor mass. (B) Amount of VEGF-A released in the vitreous fluid by case 1 and case 2. The medium was collected and used for VEGF-A
measurement as reported in Methods section. Data are reported as mean ± ESM. Median value relative to control group (as described in 22) is
reported (see dotted line). (C) H&E staining (left panels) and immunohistochemistry for VEGF-A (middle panels) and hERG1 proteins (right panels)
on case 1 and 2. Inset: magnification of the picture reported in the corresponding panel. Scale bar = 100 μm; Inset scale bar = 50 μm (D)
Immunostaining for VEGF-A and hERG1, analysis of microvessel density (MVD) and evaluation of apoptotic and proliferation index (AI and PI
respectively). The intensity of VEGF-A and hERG1 staining was also evaluated in normal retinal tissue and the percentage of positive cells was
12,2 ± 2% and 23,08 ± 8% respectively.
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(Figure 3B). The median value of VEGF-A was markedly
higher in the RB samples (987 pg/ml) when compared
to the values of the control group, reported in [22],
which refers to aged-paired patients (see Table Two
reported in [22]: 59 pg/ml; range 38-135).
Finally, we studied the distribution of the VEGF-A and
hERG1 proteins in the two tumor samples by immuno-
histochemistry. A strong immunopositivity for VEGF-A
was detected in both the RB samples analyzed (see Fig-
ure 3C): 68 ± 7% and 83 ± 6% of cells were positive for
VEGF-A staining, in case 1 and 2, respectively. Accord-
ing to the method reported in [14] most of the cells
showed a strong intensity score for both samples (see
insets of the VEGF-A panels in Figure 3C). Consistently
the microvessel density (MVD), evaluated by CD34
staining, was high, with a significant higher MVD value
in case 2 compared to case 1 (p = 0.037, t Student test)
(Figure 3D). hERG1 expression was evaluated by stain-
ing with a monoclonal anti hERG1 antibody (clone A12)
which exhibits an high specificity although with a less
intense staining (Lastraioli E, manuscript in prepara-
tion). 82 ± 4% (in case 1) and 91 ± 7% (in case 2) tumor
cells were positive for hERG1, most of them with a
moderate intensity score.
Finally, a quantitative analysis of proliferation and
apoptosis was performed. The proliferative index (PI)
was 54 ± 7% in case 1, and 78 ± 8 in case 2. Similar
levels of the apoptic index (AI) were found in both sam-
ples, with values comparable to those described in the
literature (less than 3%) [23](Figure 3D).
Conclusion
Due to early diagnosis and improved treatment meth-
ods, the survival rate of RB patients has dramatically
improved over the last 20 years [24]. In our experience,
most RB patients benefit from treatment with conserva-
tive therapy. The survival rate dramatically drops to 30%
in the cases with presence of metastasis. The presence
of metastasis is, therefore, an important feature in the
outcome of RB. Pathohistological signs of invasion of
eye structures such as the choroid, sclera, and optic
nerve anterior or posterior to the lamina cribrosa are
highly predictive for the presence of metastasis and cor-
relate with the risk of death [5,6,25]. Data on biological
factors influencing the difference in aggressiveness and
invasive potential of RB are scarce. The phenomenon of
tumor angiogenesis, as an indicator of higher malignant
potential, is repeteadly associated with tumor progres-
sion and acquirement of malignancy in solid neoplasms.
In this scenario, anti-angiogenesis therapy has been
tested as a new treatment option has been tested for
several tumors, including pediatric malignancies [12,26].
Based on current knowledge, it is believed that patients
would profit most from a combination therapy
consisting of anti-angiogenic and chemotherapeutic
drugs. Such combination therapy targets both the
endothelial compartment and the tumor cell compart-
ment, and seems to be more effective in improving the
outcome than either therapies alone. Because of the
morbidity and potential mortality (from second malig-
nancies), pediatric and ocular oncologists have sought
effective alternative methods for treating more aggres-
sive and metastatic RB. Such methods also include anti-
angiogenesis therapies targeting the angiogenic growth
factor VEGF-A, as a new option. However, a detailed
quantitative evaluation of VEGF-A and of the VEGF-A
pathway, in aggressive and metastatic RB, is still lacking.
In this manuscript we describe two cases of bilateral
RB which did not experience any benefit from conserva-
tive treatment options. We provide evidence that the
VEGF-A pathway is active in both cases, showing the
overexpression of the vegf-a, VEGF-A receptors (flt-1
and kdr) and hif1-a transcripts. Moreover, VEGF-A is
secreted at high levels in the vitreous of both RB cases,
and a strong immunoreaction for VEGF-A can be
detected in both RB specimens. Since we previously
showed that hERG1 channels regulate vegf-a expression
and VEGF-A secretion in cancer cells [19,27,28], we also
evaluated the expression level of the genes encoding
hERG1 channels as well as of the corresponding hERG1
protein in the two RB cases. We here provide evidence,
for the first time, that herg1 gene isoforms (herg1a and
herg1b) and the hERG1 protein are over expressed in
RB as occurred in many different tumors [28]. Finally,
both the microvessel density (MVD) and proliferation-
related parameters (proliferation index, (PI) and apopto-
tic index (AI)) were evaluated in both RB cases. It
emerged an interesting correlation between the levels of
VEGF-A and hERG1 and those of MVD and PI.
These results further stress the relevance of the
VEGF-A pathway in RB, making aggressive and recur-
rent RB cases good candidates for antiangiogenesis
therapies based on the targeting of VEGF- A.
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